Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Junichi, Kamata"'
Autor:
Saori Watanabe-Miyano, Kiyoshi Okamoto, Kazuki Miyazaki, Setsuo Funasaka, Yoshinobu Yamane, Yoshiharu Mizui, Yoichi Ozawa, Junichi Kamata, Keigo Tanaka, Daisuke Ito, Yoshihiko Kotake, Nagao Satoshi, Osamu Toyama
Publikováno v:
Bioorganic & Medicinal Chemistry. 22:5513-5529
Hypoxia-inducible factor-1 (HIF-1) is the chief transcription factor regulating hypoxia-driven gene expression. HIF-1 overexpression is associated with poor prognosis in several cancers and therefore represents an attractive target for novel antitumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10858306428f0891bf15ce593eb4e1cf
https://doi.org/10.1016/j.bmc.2014.07.020
https://doi.org/10.1016/j.bmc.2014.07.020
Autor:
Kazuki Miyazaki, Yoichi Ozawa, Osamu Tohyama, Isao Tanaka, Makoto Asano, Nagao Satoshi, Yoshiharu Mizui, Setsuo Funasaka, Akira Yokoi, Saori Watanabe, Takanori Kawamura, Daisuke Ito, Yoshinobu Yamane, Yoshihiko Kotake, Kohei Sawada, Kiyoshi Okamoto, Junichi Kamata, Naoko Tsukahara, Mika Aoki
Publikováno v:
International Journal of Molecular Medicine
Hypoxia-inducible factor 1 (HIF-1) activates the transcription of genes that play crucial roles in the adaptation of cancer cells to hypoxia. HIF-1α overexpression has been associated with poor prognosis in patients with various types of cancer. Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b83c096d2c3122ac21cb2a7d9b4ba1fb
https://doi.org/10.3892/ijmm.2011.875
https://doi.org/10.3892/ijmm.2011.875
Autor:
Kentaro Yoshimatsu, Katsuji Nakamura, Takeshi Nagasu, Hiroyuki Sugumi, Jun Niijima, Toshimi Okada, Toshimitsu Uenaka, Nozomu Koyanagi, Kappei Tsukahara, Atsumi Yamaguchi, Hiroshi Yoshino, Kyosuke Kitoh, Junichi Kamata, Yoshihiko Kotake
Publikováno v:
Chemical and Pharmaceutical Bulletin. 52:1071-1081
As part of a series of studies to discover new topoisomerase II inhibitors, novel pyrimidoacridones, pyrimidophenoxadines, and pyrimidocarbazoles were synthesized, and in vitro and in vivo antitumor activities and DNA-protein and/or DNA-topoisomerase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7dc5f0c0baabab56e3b6f243222fc67
https://doi.org/10.1248/cpb.52.1071
https://doi.org/10.1248/cpb.52.1071
Autor:
Junichi Kamata, et al. et al.
Publikováno v:
ChemInform. 36
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c61bf97687ebf627aae09e7bcf494884
https://doi.org/10.1002/chin.200509151
https://doi.org/10.1002/chin.200509151
Autor:
Toshimitsu Uenaka, Hiroshi Yoshino, Tomoyoshi Taniguchi, Takeshi Nagasu, Katsuji Nakamura, Yoshihiko Kotake, Nozomu Koyanagi, Hiroyuki Sugumi, Jun Niijima, Toshimi Okada, Kentaro Yoshimatsu, Atsumi Yamaguchi, Kyosuke Kitoh, Junichi Kamata
Publikováno v:
Cancer science. 94(1)
We have discovered a novel topoisomerase II (topo II) poison, ER-37328 (12,13-dihydro-5-[2-(dimethylamino)ethyl]-4H-benzo[c]pyrimido[5,6,1-jk]carbazole-4,6,10(5H,11H)-trione hydrochloride), which shows potent tumor regression activity against Colon 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93373ed80d2a520906c27a06783053c3
https://pubmed.ncbi.nlm.nih.gov/12708485
https://pubmed.ncbi.nlm.nih.gov/12708485
Autor:
Katsuji, Nakamura, Hiroyuki, Sugumi, Atsumi, Yamaguchi, Toshimitsu, Uenaka, Yoshihiko, Kotake, Toshimi, Okada, Junichi, Kamata, Jun, Niijima, Takeshi, Nagasu, Nozomu, Koyanagi, Hiroshi, Yoshino, Kyosuke, Kitoh, Kentaro, Yoshimatsu
Publikováno v:
Molecular cancer therapeutics. 1(3)
DNA topoisomerase II has been shown to be an important therapeutic target in cancer chemotherapy. Here, we describe studies on the antitumor activity of a novel topoisomerase II inhibitor, ER-37328 [12,13-dihydro-5-[2-(dimethylamino)ethyl]-4H-benzo[c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2c50add1f41eaf7458e971ba720077bf
https://pubmed.ncbi.nlm.nih.gov/12467211
https://pubmed.ncbi.nlm.nih.gov/12467211
Autor:
Yasuhiro, Funahashi, Naoko Hata, Sugi, Taro, Semba, Yuji, Yamamoto, Shinichi, Hamaoka, Naoko, Tsukahara-Tamai, Yoichi, Ozawa, Akihiko, Tsuruoka, Kazumasa, Nara, Keiko, Takahashi, Tadashi, Okabe, Junichi, Kamata, Takashi, Owa, Norihiro, Ueda, Toru, Haneda, Masahiro, Yonaga, Kentaro, Yoshimatsu, Toshiaki, Wakabayashi
Publikováno v:
Cancer research. 62(21)
In the process of angiogenesis, endothelial adhesion molecules play a significant role in vascular morphogenesis, in coordination with angiogenic factor signaling. Here we report that a novel angiogenesis inhibitor, E7820 (an aromatic sulfonamide der
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f06be61ea48cb9eb6ca0a7bb22c45741
https://pubmed.ncbi.nlm.nih.gov/12414636
https://pubmed.ncbi.nlm.nih.gov/12414636
Autor:
Katsuji Nakamura, Tomohiro Matsushima, Akihiko Tsuruoka, Junji Matsui, Yuji Yamamoto, Zoltan Dezso, Kazuki Miyazaki, Fusayo Mimura, Hiroshi Obaishi, Taro Semba, Masayuki Matsukura, Yasuhiro Funahashi, Atsumi Yamaguchi, Toru Haneda, Kenichi Nomoto, Junichi Kamata, Toshiaki Wakabayashi, Makoto Asada, Kentaro Yoshimatsu, Tatsuo Watanabe, Keiko Takahashi, Yoshio Fukuda, Sachi Hoshi, Osamu Tohyama
Publikováno v:
Vascular Cell
Background Lenvatinib is an oral inhibitor of multiple receptor tyrosine kinases (RTKs) targeting vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet growth factor receptor α (PDGFR α), RET
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cc52d269e4d1d39f62b83903bdb70bf
https://doi.org/10.1186/2045-824x-6-18
https://doi.org/10.1186/2045-824x-6-18